JONS Celebrates Breast Cancer Awareness Month

Best Practices in Breast Cancer – October 2016 Vol 7
Lillie D. Shockney, RN, BS, MAS, ONN-CG
Editor-in-Chief, JONS; Program Director, AONN+; University Distinguished Service Professor of Breast Cancer, Administrative Director, The Johns Hopkins Breast Center; Director, Johns Hopkins Cancer Survivorship Programs; Professor of Surgery and Oncology, JHU School of Medicine; Co-Creator, Work Stride-Managing Cancer at Work
shockli@jhmi.edu

Dear Navigators,

Over the past couple of decades, our country has made impressive progress in raising awareness of breast cancer. From races for the cure to pink gear on NFL fields, hardly a citizen exists who doesn’t recognize the now ubiquitous pink ribbon. As navigators, we have a close tie to breast cancer awareness campaigns because our profession has its roots in implementing programs to detect breast cancer earlier in underserved populations. Since the initial trial of a navigation program by Dr Harold Freeman, the concept has expanded to include other types of cancer and encompass all stages of cancer management from diagnosis through survivorship.

With this issue of JONS, we pay tribute to our beginnings as navigators in breast cancer management by recognizing our national breast cancer awareness month and focusing on best practices in breast cancer. In our Interview with the Innovators department, we talk with Chief Scientific Officer Paul W. Dempsey, PhD, and Chief Medical Officer Paul Y. Song, MD, of Cynvenio about their multiple-template strategy, which analyzes DNA from circulating tumor cells, circulating cell-free DNA in blood, and tissue biopsies, as well as the initiation of their clinical trial in triple-negative breast cancer. We hope you find our exchange insightful and helpful.

Additionally, we present an article about using the Breast Cancer Index to help guide treatment decisions for patients with early-stage invasive breast cancer. Further, we look at endocrine therapy options for women with breast cancer. Our own Sharon Gentry offers a timely review of the transformation of breast cancer management with information for all navigators as they support patients in the role of advocate, educator, team facilitator, and resource coordinator. Finally, we are proud to present a submission from Drs Jain, Pai, Santa-Maria, and Gradishar of Northwestern University about the state of personalized medicine in breast cancer and the biomarkers that help direct therapy.

Thank you for your loyal readership. It is our hope that this special issue of JONS strengthens your ability to care for your patients with breast cancer.

Sincerely,

Lillie D. Shockney, RN, BS, MAS
Editor-in-Chief
University Distinguished Service Professor of Breast Cancer, Depts of Surgery and Oncology; Administrative Director, The Johns Hopkins Breast Center; Director, Cancer Survivorship Programs at the Sidney Kimmel Cancer Center at Johns Hopkins; Associate Professor, JHU School of Medicine, Depts of Surgery, Oncology & Gynecology and Obstetrics;
Associate Professor, JHU School of Nursing, Baltimore, MD
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Related Articles
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Web Exclusives
On May 3, 2019, the US Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (Kadcyla; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Patients should be selected for treatment with this agent based on an FDA-approved companion diagnostic test (Ventana Medical System’s PATHWAY anti-HER-2/neu [4B5] Rabbit Monoclonal Primary Antibody assay or INFORM HER2 Dual ISH DNA Probe Cocktail assay).
Updated NCCN Breast Cancer Treatment Guideline Reflects Expanding Treatment Options for HR-Positive, HER2-Negative Disease
May 2019 Vol 10, No 5
T-DM1 Reduces Residual Invasive Disease in Patients with HER2-Positive Breast Cancer After Chemotherapy
May 2019 Vol 10, No 5
Last modified: June 9, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code